

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Sep 03, 2021

Novartis today announced that following an interim analysis of data from the CIRRUS-1 study, a decision has been taken to discontinue the trial.

- The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant. Both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids).
- Study of CFZ533 in liver transplant continues, as do studies exploring CFZ533 as a potential treatment in other conditions, such as hidradenitis suppurativa and Sjögren's syndrome.

Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, results will be shared with the broader scientific community.

Source URL: <https://prod1.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients>

List of links present in page

1. <https://prod1.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients>